Literature DB >> 19586661

Enhanced interaction between Hsp90 and raptor regulates mTOR signaling upon T cell activation.

Greg M Delgoffe1, Thomas P Kole, Robert J Cotter, Jonathan D Powell.   

Abstract

The mammalian target of rapamycin (mTOR) is an evolutionarily conserved kinase which plays a role in integrating environmental cues. mTOR signals via two complexes: TORC1, which contains the Regulatory Associated Protein of TOR (raptor), and TORC2, which contains the Rapamycin-insensitive Companion of TOR (rictor). The immunosuppressive/anti-cancer agent rapamycin inhibits TORC1 function by disrupting the mTOR-raptor interaction. In an effort to understand the downstream consequences of TORC1 activation in T cells we performed a proteomic analysis of raptor binding proteins. Using this approach we have identified Hsp90 as an activation-induced binding partner of raptor in T cells. Pharmacologic inhibition of Hsp90 leads to a decrease in raptor expression and TORC1 activity. Furthermore, full T cell activation during Hsp90 blockade leads to T cell tolerance in the form of anergy. Overall, our findings suggest that Hsp90 inhibitors might represent a novel means of promoting T cell tolerance.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19586661      PMCID: PMC2768125          DOI: 10.1016/j.molimm.2009.05.185

Source DB:  PubMed          Journal:  Mol Immunol        ISSN: 0161-5890            Impact factor:   4.407


  11 in total

1.  Inhibition of cell cycle progression by rapamycin induces T cell clonal anergy even in the presence of costimulation.

Authors:  J D Powell; C G Lerner; R H Schwartz
Journal:  J Immunol       Date:  1999-03-01       Impact factor: 5.422

Review 2.  T cell anergy.

Authors:  Ronald H Schwartz
Journal:  Annu Rev Immunol       Date:  2001-12-19       Impact factor: 28.527

Review 3.  Dissecting the mechanism of T-cell anergy with immunophilin ligands.

Authors:  Jonathan D Powell; Yan Zheng
Journal:  Curr Opin Investig Drugs       Date:  2006-11

4.  A role for mammalian target of rapamycin in regulating T cell activation versus anergy.

Authors:  Yan Zheng; Samuel L Collins; Michael A Lutz; Amy N Allen; Thomas P Kole; Paul E Zarek; Jonathan D Powell
Journal:  J Immunol       Date:  2007-02-15       Impact factor: 5.422

Review 5.  Mammalian target of rapamycin: immunosuppressive drugs uncover a novel pathway of cytokine receptor signaling.

Authors:  R T Abraham
Journal:  Curr Opin Immunol       Date:  1998-06       Impact factor: 7.486

Review 6.  mTOR and cancer: insights into a complex relationship.

Authors:  David M Sabatini
Journal:  Nat Rev Cancer       Date:  2006-08-17       Impact factor: 60.716

7.  Ablation in mice of the mTORC components raptor, rictor, or mLST8 reveals that mTORC2 is required for signaling to Akt-FOXO and PKCalpha, but not S6K1.

Authors:  David A Guertin; Deanna M Stevens; Carson C Thoreen; Aurora A Burds; Nada Y Kalaany; Jason Moffat; Michael Brown; Kevin J Fitzgerald; David M Sabatini
Journal:  Dev Cell       Date:  2006-12       Impact factor: 12.270

8.  Suppression of the mTOR-raptor signaling pathway by the inhibitor of heat shock protein 90 geldanamycin.

Authors:  Goh Ohji; Sujuti Hidayat; Akio Nakashima; Chiharu Tokunaga; Noriko Oshiro; Ken-Ichi Yoshino; Koichi Yokono; Ushio Kikkawa; Kazuyoshi Yonezawa
Journal:  J Biochem       Date:  2006-01       Impact factor: 3.387

9.  Prolonged TCR/CD28 engagement drives IL-2-independent T cell clonal expansion through signaling mediated by the mammalian target of rapamycin.

Authors:  Sara Colombetti; Veronica Basso; Daniel L Mueller; Anna Mondino
Journal:  J Immunol       Date:  2006-03-01       Impact factor: 5.422

Review 10.  Targeting the mammalian target of rapamycin (mTOR): a new approach to treating cancer.

Authors:  S Chan
Journal:  Br J Cancer       Date:  2004-10-18       Impact factor: 7.640

View more
  20 in total

Review 1.  Proteomic approaches to predict bioavailability of fatty acids and their influence on cancer and chronic disease prevention.

Authors:  Baukje de Roos; Donato F Romagnolo
Journal:  J Nutr       Date:  2012-05-30       Impact factor: 4.798

2.  FKBPs and the Akt/mTOR pathway.

Authors:  Felix Hausch; Christian Kozany; Marily Theodoropoulou; Anne-Katrin Fabian
Journal:  Cell Cycle       Date:  2013-07-01       Impact factor: 4.534

Review 3.  mTOR and metabolic regulation of conventional and regulatory T cells.

Authors:  Chaohong Liu; Nicole M Chapman; Peer W F Karmaus; Hu Zeng; Hongbo Chi
Journal:  J Leukoc Biol       Date:  2015-02-24       Impact factor: 4.962

4.  Oncolytic Viruses Engineered to Enforce Leptin Expression Reprogram Tumor-Infiltrating T Cell Metabolism and Promote Tumor Clearance.

Authors:  Dayana B Rivadeneira; Kristin DePeaux; Yiyang Wang; Aditi Kulkarni; Tracy Tabib; Ashley V Menk; Padmavathi Sampath; Robert Lafyatis; Robert L Ferris; Saumendra N Sarkar; Stephen H Thorne; Greg M Delgoffe
Journal:  Immunity       Date:  2019-08-27       Impact factor: 31.745

5.  Heat shock protein 90 is a new potential target of anti-rejection therapy in allotransplantation.

Authors:  Takeshi Maehana; Toshiaki Tanaka; Kohei Hashimoto; Ko Kobayashi; Hiroshi Kitamura; Naoya Masumori
Journal:  Cell Stress Chaperones       Date:  2022-04-09       Impact factor: 3.827

Review 6.  MenTORing Immunity: mTOR Signaling in the Development and Function of Tissue-Resident Immune Cells.

Authors:  Russell G Jones; Edward J Pearce
Journal:  Immunity       Date:  2017-05-16       Impact factor: 31.745

7.  Targeting TOR dependence in cancer.

Authors:  Matthew R Janes; David A Fruman
Journal:  Oncotarget       Date:  2010-05

8.  Disruption of an hTERT-mTOR-RAPTOR protein complex by a phytochemical perillyl alcohol and rapamycin.

Authors:  Tabetha Sundin; Dennis M Peffley; Patricia Hentosh
Journal:  Mol Cell Biochem       Date:  2013-01-03       Impact factor: 3.396

9.  TSC1 regulates the balance between effector and regulatory T cells.

Authors:  Yoon Park; Hyung-Seung Jin; Justine Lopez; Chris Elly; Gisen Kim; Masako Murai; Mitchell Kronenberg; Yun-Cai Liu
Journal:  J Clin Invest       Date:  2013-11-25       Impact factor: 14.808

10.  The kinase mTOR regulates the differentiation of helper T cells through the selective activation of signaling by mTORC1 and mTORC2.

Authors:  Greg M Delgoffe; Kristen N Pollizzi; Adam T Waickman; Emily Heikamp; David J Meyers; Maureen R Horton; Bo Xiao; Paul F Worley; Jonathan D Powell
Journal:  Nat Immunol       Date:  2011-02-27       Impact factor: 25.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.